🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Let's spread the word! Daniel E Spratt Amar Kishan Pierre Blanchard, MD Himanshu Nagar Chad Tang, MD Shankar Siva Paul Sargos Paul Nguyen Audrey Li Danny Vesprini Dr Stanley Liu Felix Feng ASTRO Chair Howard Sandler Howard Sandler Neha Vapiwala

Last chance for early discounted rates—register by Friday, October 25. This program covers cutting-edge strategies for bladder & kidney cancers, with expert-led discussions from top surgeons, oncologists, radiologists & more. Secure your spot today: bit.ly/URO2024 Key

Lovely visit with ⁦The Royal Marsden NHS Foundation Trust⁩. Thank you to our incredible host ⁦Alison Tree 💙 and always great to learn and chat with⁩ ⁦Robert Huddart💙⁩ ⁦Nicholas van As⁩ ⁦Chris Parker⁩ among many others on this incredible GU team on every topic in the field.

Very pleased that CMSGov followed the evidence and decided to continue to allow telehealth for status checks (77427). This is clearly the right decision: it preserves access for patients and gives doctors the discretion to provide care in the way they and their patients think

Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer pubmed.ncbi.nlm.nih.gov/39493817/ 🚨New Article🚨 Sharing position paper on eligibility and endpoints for bladder preservation trials. co-author by Leslie Ballas splernerMD Guru P. Sonpavde, MD Ronald Chen

Fill out an application to run the 2025 TCS New York City Marathon with Fred's Team to raise money for cancer research Memorial Sloan Kettering Cancer Center. fredsteam.org/events/tcs-new…

POSITION PAPER: Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer by Ronald Chen, splernerMD, Guru P. Sonpavde, MD, Himanshu Nagar, Parminder singh et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… Dr. Bishoy M. Faltas Dan Theodorescu

Pleased to share 2-year outcomes from the MIRAGE trial, evaluating toxicity following prostate SBRT using either aggressive margin reduction to 2 mm leveraging MRI-guidance or a 4 mm with standard CT-guidance authors.elsevier.com/sd/article/S03… European Urology UCLA Health

Reminder: The 2024 Update on the Multimodality Management of Bladder & Kidney Cancer is just around the corner! Our multidisciplinary team of experts will provide a state-of-the-art update on neoadjuvant & adjuvant therapies, treatment paradigms, optimal surgical approaches,

Great to see so many friends and colleagues committed to innovative and practice-changing clinical trials at NRG Oncology in Phoenix. 2025 will be a big year for bladder preservation with NRG launching 2 randomized trials looking at adaptive (20 vs 5 fractions) chemoRT in MIBC

Thank you to Misha Beltran and Himanshu Nagar for organizing this year’s Feng Symposium. Felix would have loved to catch up with his friends and talk about a new crazy way to change the world. A reminder to collaborate and take care of each other. UCSF Helen Diller Family Comprehensive Cancer Ctr ASCO ASTRO

Protocol Activation! NRG-GU014 - Randomized Phase II Trial Of Pembrolizumab and Radiation vs. Radiation And Concurrent Chemotherapy For High-Grade T1 Bladder Cancer (PARRC Trial) Brian C. Baumann Scott Delacroix M.D.

POTEN-C: Nerve-sparing SAbR (NV-SAbR) in PCa: Neil Desai #ESTRO25 Results at 3mo 🛡️🧠 Less nerve damage ⬇️🧻 Fewer bowel/bladder side effects ⬆️🚀 Better sexual function ➡️ Even at higher radiation doses! Smarter treatment = better quality of life.

An absolute pleasure hosting you at Memorial Sloan Kettering Cancer Center! Your seminar on bladder-preserving therapy was both inspiring and thought-provoking. Grateful for your visit and for advancing the conversation in #BladderCancer care.

Amazing work by the study team and encourage reading the accompanying editorial (Sean McBride). Many questions still need to be answered in the post-RP setting. jamanetwork.com/journals/jamao…

REGISTER TODAY! Want to learn more about NRG-GU012 the SAMURAI study of SABR for patients w/ unresected #renalcell carcinoma receiving #immunotherapy? Our Study PIs will be hosting a webinar on Friday June 13th from 12-1pm ET/9-10am PT. Register here: ow.ly/xF8s50Vqq63

🔥Restriction Spectrum Imaging as a quantitative biomarker for prostate cancer with reliable positive predictive value | Journal of Urology Amer. Urol. Assn. auajournals.org/doi/10.1097/JU… Congrats Tyler Seibert MD PhD and team.

Another great ICECAP study showing in large 4 study IPD meta, addition of Doce to RT+ADT did not significantly improve OS. meetings.asco.org/abstracts-pres… Aligns with current National Comprehensive Cancer Network (NCCN) to not recommend Doce using current risk stratification methods for non-M1 disease. Most high risk dz

Despite RP + RT patients generally younger/healthier than RT patients (and very outdated RT), this observational non-randomized study shows RP+RT have highest risk of urinary adverse events. Important counseling for high risk PCa given trials consistently demonstrate ~80% will